Xanamem® in Adults with Major Depressive Disorder and Impaired Cognition (XanaCIDD)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2022
Xanamem is being developed as a potential treatment for symptomatic, early stages ofAlzheimer's Disease (AD) and Major Depressive Disorder (MDD).This XanaCIDD Phase II study in MDD is to investigate the safety and efficacy of Xanamem™in treating patients with cognitive and depressive symptoms. Trial participants will berandomized to either receive 10mg of Xanamem™ once daily or a Placebo at a 1:1 ratio in adouble‐blinded fashion.
Epistemonikos ID: 259aedb56cc31fbdcd2121ad8b2e85ca070fbbd4
First added on: Oct 02, 2023